Award
NIH Reporter #5R44HL160338-03
Minimizing myocardial damage and loss of cardiac function post myocardial infarction using Targeted PKC inhibitors 002 and 004.
Recipient
Young Therapeutics, LLC
Award Amount
$1,488,899.00
Ceiling
$1,488,899.00
Awarded
June 30, 2026
Identifier
5R44HL160338-03
Funding supports development of targeted PKC inhibitors intended to reduce heart damage and preserve cardiac function after myocardial infarction.
Description
Phase II SBIR project to develop and validate YT-002 and YT-004, compounds targeting PKCε and PKCβII, to preserve myocardial tissue and function after infarction. The work includes formulation optimization, pharmacokinetic and pharmacodynamic studies, and long-term safety and efficacy studies in porcine models to support potential IND applications.